Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines

British Journal of Pharmacology

Volumn 120, Issue 3, 1997, Pages 537-543

  De Cupis, Alessandra ^a   Ciomei, Marina ^b   Pirani, Paolo ^a   Ferrera, Alessandra ^a   Ardizzoni, Andrea ^a   Favoni, Roberto Enrico ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b PFIZER INC   (United States)

Author keywords

Distamycin A derivatives; Human lung cancer cells; Insulin like growth factor I

Indexed keywords

DISTAMYCIN A DERIVATIVE; FCE 26644; FCE 27784; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SURAMIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; CYTOSTASIS; DNA SYNTHESIS; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR BINDING; RECEPTOR DOWN REGULATION;

EID: 0031027921     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0700937     Document Type: Article

References (34)

1. AARONSON, S.A. (1991). Growth factors and cancer. Science, 254, 1146-1153.
2. ARCAMONE, F.M., ANIMATI, F., BARBIERI, B., CONFIGLIACCHI, E., D'ALESSIO R, GERONI, C., GIULIANI, F.C., LAZZARI, E., MENOZZI, M., MONGELLI, N., PENCO, S. & VERINI, A. (1989). Synthesis. DNA-binding properties and antitumor activity of novel distamycin A derivatives. J. Med. Chem., 32, 774-778.
3. BIASOLI, G., BOTTA, M., CIOMEI, M., CORELLI, F., GRANDI, M., MANETTI, F., MONGELLI, N. & PAIO, A. (1993). New heterocyclic analogues of suramin with bFGF inhibiting activity. Synthesis, SAR and possible mode of action. Med. Chem. Res., 4, 202-210.
4. CARMICHAEL J., DEGRAFF, W.G., GAZDAR, A.F., MINNA, J.D. & MITCHELL, J.B. (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47, 936-942.
5. CIOMEI, M., PASTORI, W., MARIANI, M., SOLA, F., GRANDI, M. & MONGELLI, N. (1994). New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem. Pharmacol., 47, 295-302.
6. CRISTIANI, C., GALVANI, A.P., LANDONIO, A., PORTELLO, C., MONGELLI, N. & BERTOLERO, F. (1995). Hepatocyte growth factor receptor activation and scatter activity are inhibited by novel suramin-like molecules. Cell. Pharmacol., 2, 43-48.
7. CROSS, M. & DEXTER, T.M. (1991). Growth factors in development, transformation and tumorigenesis. Cell, 64, 271-289.
8. DE CUPIS, A., NOONAN, D., PIRANI, P., FERRERA, A., CLERICO, L. & FAVONI, R.E. (1995). Comparison between novel steroidal-like and conventional nonsterioidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells. Br. J. Pharmacol., 116, 2391-2400.
9. FAVONI, R.E., DE CUPIS, A., PERROTTA, A., SFORZINI, S., AMOROSO, D., PENSA, F. & MIGLIETTA, L. (1995). Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status. J. Cancer Res. Clin. Oncot., 121, 674-682.
10. FAVONI, R.E., DE CUPIS, A., RAVERA, F., CANTONI, C., PIRANI, P., ARDIZZONI, A., NOONAN, D. & BIASSONI, R. (1994a). Expression and function of the insulin-like growth factor-I system in human non-small cell lung cancer and normal lung cell lines. Int. J. Cancer, 56, 858-866.
11. FAVONI, R.E., RAVERA, F., PIRANI, P., ARDIZZONI, A., NOONAN, D. & DE CUPIS, A. (1994b). Suramin interferes with auto/ paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines. Eur. J. Pharmacol., 264, 199-206.
12. FOLKMAN, J. & KLAGSBRUN, M. (1987). Angiogenic factors. Science, 235, 442-447.
13. GARFINKEL, L. & MUSHINSKI, M. (1994). Cancer incidence, mortality and survival: trends in four leading sites. Stat. Bull. Metrop. Insur. Co., 75, 19-27.
14. HOLLAND, E.J., STEIN, C.A., PALESTINE, A.G., LA ROCCA, R., CHAN, C., KUWABARA, T., MYERS, R., THOMAS, R., MCATEE, N. & NUSSEMBLAT, R. (1988). Suramin keropathy. Am. J. Ophthalm., 106, 216-220.
15. HORNE, MCDK., STEIN, C.A. & LA ROCCA, R.V. (1988). Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood, 71, 273-279.
16. HOSANG, M. (1985). Suramin binds to platelet-derived growth factor and inhibits its biological activity. J. Cell Biol., 24, 265-273.
17. LEVI, F., LUCCHINI, F. & LA VECCHIA, C. (1994). Worldwide patterns of cancer mortality, 1985-1989. Eur. J. Cancer Prev., 3, 109-143.
18. LOPEZ-LOPEZ, R., PETERS, G.J., VAN LEONEN, A.C., PIZAO, P.E., VAN RIJSWIJK, R.E.N., WAGSTAFF, J. & PINEDO, H.M. (1992). The effect of schedule, protein binding and growth factors on the activity of suramin. Int. J. Cancer, 51, 921-926.
19. MACAULAY, V.M. (1992). Insulin-like growth factor and cancer. Br. J. Cancer, 65, 311-320.
20. MACAULAY, V.M., EVERARD, M.J., TEALE, J.D., TROTT, PA., VAN WYK, J.J., SMITH, I.E. & MILLAR, J.L. (1990). Autocrine function of insulin-like growth factor I in human small-cell lung cell lines and fresh tumor cells. Cancer Res., 50, 2511-2517.
21. MACAULAY, V.M., TEALE, J.D., EVERARD, M.J., JOSHI, G.P., SMITH, I.E. & MILLAR, J.L. (1988). Somatomedin-C/insulin-like growth factor-1 is a mitogen for human small-cell lung cancer. Br. J. Cancer, 57, 91-95.
22. McPHERSON, G.A. (1985). Analysis of radioligand binding experiments: a collection of computer programs for the IBM PC. J. Pharmacol. Methods, 14, 213-228.
23. MINNA, J.D., PASS, H. & GLATSTEIN, E. (1989). Cancer of the lung in De Vita V.T.J., In Cancer: Principles and Practice of Oncology. (ed.3). ed. De Vita, V.T.J., Hellman, S. & Rosenberg, S.A. pp. 595-705, Philadelphia P.A.: Lippincott.
24. MINUTO, F., DEL MONTE, P., BARRECA, A., FORTINI, P., CARIOLA, G., CATRAMBONE, G. & GIORDANO, G. (1986). Evidence for an increased somatomedin/C/insulin-like growth factor-I content in primary human lung tumours. Cancer Res., 46, 985-988.
25. PAVELIC, K., VRBANEK, D., MARUSIC, S., LEVANAT, S. & CABRIJAN, T. (1986). Autocrine tumor-growth regulation by somatomedin-C: an in vitro model. J. Endocrinology, 109, 223-238.
26. PESENTI, E., SOLA, F., MONGELLI, N., GRANDI, M. & SPREAFICO, F. (1992). Suramin prevents neovascularisation and tumor growth through blocking of basic fibroblast growth factor activity. Int. J. Cancer, 66, 367-372.
27. POLLAK, M. & RICHARD, M. (1990). Suramin blockade of insulin-like growth factor-I-stimulated proliferation of human osteosarcoma cells. J. Natl. Cancer Inst., 82, 1349-1352.
28. RAVERA, F., MIGLIETTA, L., PIRANI, P., FERRINI, S. & FAVONI, R.E. (1993). Suramin-induced growth inhibition and IGF-I binding blockade on human breast cancer cell lines: potentially related events. Eur. J. Cancer, 29A, 225-230.
29. SOLA, F., FARAO, M., PESENTI, E., MARSIGLIO, A., MONGELLI, N. & GRANDI, M. (1995). Antitumor activity of FCE 26644, a new growth factor-complexing molecule. Cancer Chemother. Pharmacol., 36, 217-222.
30. SPORN, M.B. & ROBERTS, A.B. (1985). Autocrine growth factors and cancer. Nature , 313, 745-747.
31. STEIN, C.A., LA ROCCA, R.V., THOMAS, R., McATEE, N. & MYERS, C.E. (1989). Suramin: an anticancer drug with a unique mechanism of action. J. Clin. Oncol., 7, 499-508.
32. YARDEN, Y. & ULLRICH, A. (1988). Growth factor receptor tyrosine kinases. Annu. Rev. Biochem., 57, 443-478.
33. YEE, D., ROSEN, N., FAVONI, R.E. & CULLEN, K.J. (1991). The insulin-like growth factors, their receptor and their binding proteins in human breast cancer. In Regulatory Mechanisms In Breast Cancer, ed. Lippman, M. & Dickson, R. pp. 93-106. Boston, MA: Kluwer.
34. ZUGMAIER, G., LIPPMAN, M.E. & WELLSTEIN, A. (1992). Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J. Natl. Cancer Inst., 84, 1716-1724.